AstraZeneca has unveiled new data showing a statistically-significant reduction in hospitalisation for heart failure or cardiovascular (CV) death in a broad population of patients with type II diabetes taking Farxiga.
Virtual biotech Keapstone Therapeutics is in line for a further £1 million investment from Parkinson’s UK to move forward its innovative disease-modifying therapeutic approach to motor neuron disease (MND) and Parkinson’s.
The European Commission (EC) has granted marketing authorisation for Pierre Fabre’s Braftovi and Mektovi combination therapy for the treatment of adults with unresectable or metastatic melanoma with a BRAFV600 mutation.
New from PharmaTimes Media is the Medical & Scientific Excellence Awards.Highlighting this important area of work within the pharmaceutical industry, the awards are designed to recognise the outstanding achievements of medical and scientific professionals.
The Association of the British Pharmaceutical Industry (ABPI) is linking arms with the Academic Health Science Network in a five-year partnership that strives to accelerate uptake of transformative biomedical innovations by the NHS
Cancer Research UK is partnering with European cancer research charities AIRC (Associazione Italiana per la Ricerca sul Cancro) and FC AECC (Asociación Española Contra el Cáncer) to invest around £30 million in six international collaborations aiming to accelerate progress in translational research.